Fortis Healthcare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Fortis Healthcare Ltd filed with BSE on 11 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Fortis Healthcare reported consolidated revenue of INR 2,545 crores for Q1 FY27, up 17.5% year-on-year, with hospital revenue growing 19% and diagnostic gross revenue growing 10.2%. Consolidated operating EBITDA pre-ESOP increased 15.8% to INR 568 crores, while margin moderated slightly due to new hospital acquisitions, legal costs, and higher provisions for doubtful debt. Management discussed bed expansion, an O&M entry into Odisha, ESOP costs for clinical staff, and continued guidance toward a 25% hospital EBITDA margin by FY28.
Numbers mentioned
Consolidated revenue: INR 2,545 crores (Q1 FY27)
p. 3
“We reported consolidated revenue of INR 2,545 crores, a growth of 17.5% over Q1 of financial year '26.”
Ashutosh Raghuvanshi, page 3 of the filed PDF · View the filing
Hospital business revenue: INR 2,187 crores (Q1 FY27)
p. 3
“Noticeably, our hospital business revenues have grown by 19% to INR 2,187 crores while Q1 financial year '27 diagnostic business gross revenue has grown up by 10.2% to INR 407 crores versus the previous corresponding quarter.”
Ashutosh Raghuvanshi, page 3 of the filed PDF · View the filing
Consolidated operating EBITDA pre-ESOP: INR 568 crores (Q1 FY27)
p. 3
“Our consolidated operating EBITDA pre-ESOP expenses increased by 15.8% to INR 568 crores, delivering a margin of 22.3% versus 22.6% in Q1 of financial year '26.”
Ashutosh Raghuvanshi, page 3 of the filed PDF · View the filing
Hospital business operating EBITDA: INR 471 crores (Q1 FY27)
p. 3
“The hospital business reported an operating EBITDA of INR 471 crores, which translates into a margin of 21.5% compared to 22.1% in Q1 of financial year '26.”
Ashutosh Raghuvanshi, page 3 of the filed PDF · View the filing
Diagnostic business EBITDA margin: 23.9% (Q1 FY27)
p. 4
“The operating EBITDA margin of the Diagnostic business for the quarter improved to 23.9% from 23% in quarter 1 of financial year '26.”
Ashutosh Raghuvanshi, page 4 of the filed PDF · View the filing
Consolidated profit after tax before exceptional items: INR 263 crores (Q1 FY27)
p. 4
“Our consolidated reported profit after tax before exceptional items for the quarter increased by approximately 4% to INR 263 crores.”
Ashutosh Raghuvanshi, page 4 of the filed PDF · View the filing
Net debt: INR 2,233 crores (as of June 30, 2026)
p. 4
“On the balance sheet front, the company's net debt stands at INR 2,233 crores with a net debt-to-EBITDA ratio of 1.01x as of June 30, 2026, as against 0.92x on June 30, 2025.”
Ashutosh Raghuvanshi, page 4 of the filed PDF · View the filing
Hospital occupancy: 69% (Q1 FY27)
p. 4
“Our hospital occupancy in Q1 of financial year '27 remained steady at 69% compared to the corresponding period last year.”
Ashutosh Raghuvanshi, page 4 of the filed PDF · View the filing
ARPOB: INR 2.71 crores per annum (Q1 FY27)
p. 4
“After factoring in our recent acquisitions, the hospital business recorded an increase in ARPOB of 2.6%, reaching INR 2.71 crores per annum.”
Ashutosh Raghuvanshi, page 4 of the filed PDF · View the filing
International business revenue: INR 174 crores (Q1 FY27)
p. 4
“Revenue from international business grew 13.3% compared to Q1 of financial year '26 to reach INR 174 crores.”
Ashutosh Raghuvanshi, page 4 of the filed PDF · View the filing
Diagnostics gross revenue: INR 407 crores (Q1 FY27)
p. 5
“During the quarter, we reported gross revenue of INR 407 crores, reflecting a 10.2% year-on-year growth over Q1 last year.”
Vijender Singh, page 5 of the filed PDF · View the filing
Diagnostics operating EBITDA: INR 97 crores (Q1 FY27)
p. 5
“Operating EBITDA grew to INR 97 crores, while operating EBITDA margins improved to 23.9%, compared to 23.0% in the corresponding quarter last year.”
Vijender Singh, page 5 of the filed PDF · View the filing
Tests processed: approximately 10.5 million (Q1 FY27)
p. 5
“Operationally, we processed approximately 10.5 million tests during the quarter and expanded our network with the gross addition of over 200 customer touch points.”
Vijender Singh, page 5 of the filed PDF · View the filing
B2C:B2B revenue mix: 53:47 (Q1 FY27)
p. 5
“we also saw continued momentum in our consumer business with the B2C:B2B revenue mix improving to 53:47 in Q1 FY '27 from 51:49 in Q1 FY '26.”
Vijender Singh, page 5 of the filed PDF · View the filing
Gleneagles management fee: Around INR 6 crores (Q1 FY27)
p. 13
“Around INR 6 crores.”
Vivek Goyal, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Hospital EBITDA margin — 25% · FY28
stated firmly by Vivek Goyal
p. 8
“we are still maintaining our guidance. The quarter-on-quarter may not be that way. Like in this quarter, there is a dip if we consider ESOP cost. Overall, in two years’ time, we are quite hopeful that we will be reaching to 25%.”
Vivek Goyal, page 8 of the filed PDF · View the filing
Hospital EBITDA margin (ESOP-inclusive) — 25%
stated as an aspiration by Vivek Goyal
p. 9
“We are aspiring to achieve 25% EBITDA margin after running the ESOP cost.”
Vivek Goyal, page 9 of the filed PDF · View the filing
Bed additions — 400 beds · remaining 3 quarters of the year
stated firmly by Vivek Goyal
p. 9
“We are expecting to operationalize another 400 beds in the remaining 3 quarters of the year.”
Vivek Goyal, page 9 of the filed PDF · View the filing
Manesar and Greater Noida EBITDA margin — mid-teens · by year-end
stated conditionally by Ashutosh Raghuvanshi
p. 8
“Both these hospitals, by the year-end, certainly be in the mid-teens as far as EBITDA is concerned, if not higher.”
Ashutosh Raghuvanshi, page 8 of the filed PDF · View the filing
ESOP charge — around INR 25 crore per quarter · third year
stated firmly by Vivek Goyal
p. 9
“the charge will be somewhere around INR 40 crore per quarter, and thereafter it should fall down to around INR 30 crore. In the third year, it should be around INR 25 crore per quarter.”
Vivek Goyal, page 9 of the filed PDF · View the filing
Occupancy improvement — another 2% to 3% percentage points
stated as an aspiration by Vivek Goyal
p. 13
“I think all these levers will be good enough to ramp up the occupancy going forward by another 2% to 3%, percentage point.”
Vivek Goyal, page 13 of the filed PDF · View the filing
Diagnostics revenue growth — around 12%-13%
stated firmly by Vivek Goyal
p. 15
“we are expecting the revenue growth to be around 12%-13%, and EBITDA margin should be in the range of 24%- 25% for the remaining time.”
Vivek Goyal, page 15 of the filed PDF · View the filing
Oncology growth — 10%-12%
stated as an aspiration by Ashutosh Raghuvanshi
p. 12
“But certainly, this is going to be in the range of 10%, 12% and not like 27%, which used to be earlier.”
Ashutosh Raghuvanshi, page 12 of the filed PDF · View the filing
Capex — around 50% of EBITDA · this year
stated firmly by Vivek Goyal
p. 14
“Without taking any acquisitions into consideration, we will be consuming around 50% of our EBITDA for our growth which is brownfield expansion which is going on.”
Vivek Goyal, page 14 of the filed PDF · View the filing
Proton therapy capex — INR 252-odd crores
stated conditionally by Vivek Goyal
p. 11
“It is under finalization, it will be in the range of INR 252-odd crores. ”
Vivek Goyal, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Charge will initially be higher and gradually reduce; margin guidance maintained.
Answered by Vivek Goyal
Asked by Tausif: What is the ESOP charge expected for FY27 and next two years, and can margin improve by 100 bps?
p. 7
“The charge will be there for next 3 year or so, the charge will initially be higher because it depend on the vesting, then it will gradually come down.”
Vivek Goyal, page 7 of the filed PDF · View the filing
Management said the ESOP charge has now come with offsetting operating improvements, and guidance stays intact.
Answered by Ashutosh Raghuvanshi
Asked by Neha Manpuria: Is the 25% margin guidance by FY28 pre-ESOP?
p. 7
“our guidance and our target does not change because we have several brownfield facilities which are coming online now, and the FMRI facility has just got ready and the final approvals are in place now.”
Ashutosh Raghuvanshi, page 7 of the filed PDF · View the filing
Growth in top line met expectations, but profitability lagged; oncology commissioning expected to change dynamics.
Answered by Ashutosh Raghuvanshi
Asked by Neha Manpuria: When will Manesar and Greater Noida reach 20% margins?
p. 8
“The growth in this top line has been as per our expectations. But the profitability has not been in line with what we had expected.”
Ashutosh Raghuvanshi, page 8 of the filed PDF · View the filing
New units, legal costs, and doubtful debt provisions were cited as current drags, expected to reverse.
Answered by Vivek Goyal
Asked by Karan Vora: What are the levers to reach 25% EBITDA margin?
p. 8
“In the current EBITDA margin trajectory, these units have contributed negatively by 0.4% to the overall EBITDA margin. I am expecting this should contribute maybe at 1% positive.”
Vivek Goyal, page 8 of the filed PDF · View the filing
Odisha is only an O&M project with no capital commitment; core strategy remains cluster-focused.
Answered by Ashutosh Raghuvanshi
Asked by Damayanti Kerai: How is the company approaching expansion into new markets like Odisha versus its cluster strategy?
p. 10
“If you would have noticed, the hospital in Odisha is only an O&M project, so we are not committing any capital to that market at the moment.”
Ashutosh Raghuvanshi, page 10 of the filed PDF · View the filing
Operations have improved but are not yet fully stabilized to Fortis standards.
Answered by Ashutosh Raghuvanshi
Asked by Damayanti Kerai: What is the status of Gleneagles hospital stabilization?
p. 11
“We have not got it to the Fortis standard, so that will take some time. Our expectation is that it should take at least 2, 3 quarters or maybe around 4 quarters before we can say that these are fully stabilized.”
Ashutosh Raghuvanshi, page 11 of the filed PDF · View the filing
New management acknowledged the growth lag and cited brand transition factors, targeting recovery.
Answered by Ashutosh Raghuvanshi
Asked by Aman Goyal: Why is diagnostics growth slower than industry peers?
p. 12
“we do recognize that there has been a muted growth or rather kind of a stagnant period for some time, and that was a variety of factors, including the brand change, et cetera.”
Ashutosh Raghuvanshi, page 12 of the filed PDF · View the filing
Chemo drug pricing discounts for ECHS/CGHS beneficiaries impacted growth.
Answered by Ashutosh Raghuvanshi
Asked by Aman Goyal: What caused the decline in oncology specialty mix?
p. 12
“the chemo drug pricing mechanism which they have come up with 30% discount on MRP is the one which is causing this dip.”
Ashutosh Raghuvanshi, page 12 of the filed PDF · View the filing
Management confirmed active pursuit of deals within focus clusters, without disclosing specifics.
Answered by Vivek Goyal
Asked by Saion Mukherjee: What is the capex guidance and are inorganic acquisitions planned?
p. 14
“Inorganic, we are actually looking at it and there are some deals which we are actively pursuing. Until those are concluded, we can't speak much about those deals.”
Vivek Goyal, page 14 of the filed PDF · View the filing
Roughly 55-60% went to doctors and administrative staff combined.
Answered by Vivek Goyal
Asked by Saion Mukherjee: What is the ESOP allocation policy across doctors and staff?
p. 14
“Roughly, it is around 55% to 60% of doctor and administrative staff including operator.”
Vivek Goyal, page 14 of the filed PDF · View the filing
Risks flagged
Legal costs from ongoing Delhi High Court hearings impacting profitability
p. 9
“Because of the ongoing Delhi High Court hearing, if you people are aware. There were intense hearings which happened last quarter as well as in this quarter, and that legal cost has also burdened the profitability if we compare with the quarter 1 of the last year.”
Vivek Goyal, page 9 of the filed PDF · View the filing
Rising provision for doubtful debt due to delays in government and TPA collections
p. 9
“the provision for doubtful debt has slightly gone up for this quarter because of various certain delays in getting collection from the government payor as well as some of the TPA.”
Vivek Goyal, page 9 of the filed PDF · View the filing
Chemo drug pricing discount mechanism affecting oncology growth
p. 12
“in all these categories, the chemo drug pricing mechanism which they have come up with 30% discount on MRP is the one which is causing this dip.”
Ashutosh Raghuvanshi, page 12 of the filed PDF · View the filing
Localized clinical staff attrition when new hospitals open in a micro market
p. 14
“when a new hospital opens, then obviously there will be some disturbance in that local geography.”
Ashutosh Raghuvanshi, page 14 of the filed PDF · View the filing
New units in ramp-up stage dragging on EBITDA margin
p. 8
“these units have contributed negatively by 0.4% to the overall EBITDA margin.”
Vivek Goyal, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.